- Home
- NOMA vs ZNTL Comparison
NOMA vs ZNTL Comparison
Compare NOMA & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NOMA | ZNTL |
|---|---|---|
| Founded | 2023 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.0M | 118.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | NOMA | ZNTL |
|---|---|---|
| Price | $4.35 | $2.95 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $5.87 |
| AVG Volume (30 Days) | 317.6K | ★ 2.6M |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $885,694.00 | ★ $26,865,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.35 | $1.01 |
| 52 Week High | $57.70 | $3.95 |
Technical Indicators
Market Signals| Indicator | NOMA | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 66.51 |
| Support Level | N/A | $1.31 |
| Resistance Level | N/A | $3.95 |
| Average True Range (ATR) | 0.00 | 0.37 |
| MACD | 0.00 | 0.14 |
| Stochastic Oscillator | 0.00 | 62.50 |
Price Performance
Historical ComparisonAbout NOMA NOMADAR Corp.
Nomadar Corp operates at the intersection of sports and technology, focusing on high-performance training programs and cultural exchange. The company aims to connect athletes, coaches, and fans through innovative technological solutions, enhancing sports development beyond physical borders. It offers services like the High Performance Training (HPT) program and promotes the legacy of iconic athletes.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.